TCGA-CN-6024-01A-11R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.076940639
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.560
- MYOGENESIS+0.500
- MYC_TARGETS_V2+0.490
- CHOLESTEROL_HOMEOSTASIS+0.420
- HEDGEHOG_SIGNALING+0.380
- HYPOXIA+0.380
- MTORC1_SIGNALING+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- UV_RESPONSE_UP+0.260
- TGF_BETA_SIGNALING+0.250
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.660
- INTERFERON_GAMMA_RESPONSE-0.590
- ALLOGRAFT_REJECTION-0.550
- IL6_JAK_STAT3_SIGNALING-0.440
- COMPLEMENT-0.400
- INFLAMMATORY_RESPONSE-0.330
- PANCREAS_BETA_CELLS-0.270
- COAGULATION-0.260
- KRAS_SIGNALING_UP-0.150
- PI3K_AKT_MTOR_SIGNALING-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-6798-01A-11R-1949-07 | — | cohortSQ2 | 0.825 |
| 2 | TCGA-22-5482-01A-01R-1635-07 | — | cohortSQ2 | 0.811 |
| 3 | TCGA-43-A474-01A-11R-A24H-07 | — | cohortSQ2 | 0.784 |
| 4 | TCGA-43-6770-01A-11R-1820-07 | — | cohortSQ2 | 0.777 |
| 5 | TCGA-63-5128-01A-01R-1443-07 | — | cohortSQ2 | 0.774 |
| 6 | TCGA-85-A4CN-01A-11R-A24H-07 | — | cohortSQ2 | 0.768 |
| 7 | TCGA-CV-5435-01A-01R-1686-07 | — | — | 0.766 |
| 8 | TCGA-CQ-5332-01A-01R-1686-07 | — | — | 0.761 |
| 9 | SRR11296875 | — | — | 0.760 |
| 10 | SRR12475151 | — | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.560 | Inavolisib | — uncovered |
| MYOGENESIS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.420 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.380 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.260 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |